Adjuvant Therapies for the Mitigation of Chemotherapy-Induced Toxicities: APIs, Formulation Strategies, and Regulatory Perspectives

Cancer treatment commonly utilizes chemotherapy as a primary method either alone or with the help of other methods. A major drawback of chemotherapy is that it creates toxicity against all cells of your body due to its non-selectiveness; this results in dose limiting toxicities, which may be experienced through nausea/vomiting, cardiotoxicity, neuropathy or myelosuppression. These side effects add up to creating substantial financial, psychological, and physical barriers for cancer patients. ^{[1, 2]} Modern approaches to supportive cancer care are beginning to focus on proactive, evidence-based strategies rather than traditional reactionary methods to minimize these side effects. Chemotherapy induced nausea/vomiting occurs in 70-80% of patients without prophylactic medication management in place; and febrile neutropenia and peripheral neuropathy are additional reasons for poor treatment outcomes. Examples of some of the major advancements that have been introduced to supportive oncology therapeutic options include pharmacologic agents (e.g., antiemetics; G-CSF; dexrazoxane; duloxetine) that have all become part of globally accepted clinical standards of treatment. ^[3,4,5] Advanced drug delivery innovations such as liposomes and nanoparticles also contribute to increased safety/accuracy during administration of chemotherapy drugs. While nutraceuticals (e.g., curcumin; probiotics) have demonstrated positive outcomes regarding supportive oncological treatment, additional validation studies are necessary prior to including nutraceuticals in global treatment guidelines.  Overall this literature review will highlight a systematic approach using pharmacologic (drug), nutraceutical (nutrition-based), and formulation methods of intervention in order to enhance supportive cancer care. ^[6,7]

2. Classification of Chemotherapy and Its Side Effects

The same cytotoxic mechanism that enables chemotherapy to destroy malignant cells also accounts for its deleterious effects on normal tissues, particularly those with rapid turnover rates. This unintended injury manifests as a broad range of toxicities that can limit dosing, interrupt treatment schedules, and degrade patients’ quality of life. The following subsections categorize the principal adverse effects of chemotherapy, outlining their clinical implications and preventive strategies.^[8]

Table 1. Common Cancers and Their Chemotherapy Regimens

 3.pharmacological Adjuvant Therapies and Their Role in Chemotherapy      Toxicity

Chemotherapy-induced toxicities continue to represent a major challenge for clinicians and patients alike, frequently restricting dose intensity and diminishing quality of life. Pharmacologic adjuvant therapies—ranging from receptor antagonists to cytoprotective agents—form the backbone of strategies to mitigate these adverse effects.^[9] Each class targets a specific biological mechanism to preserve normal tissue integrity while sustaining anticancer efficacy. The following subsections summarize key categories of pharmacologic adjuvants, outlining their mechanisms, evidence base, and clinical applications. ^[10]

Table 2: Adjuvant API used in chemotherapy

4. Natural and Nutraceutical Adjuvant Therapies

The rising interest in natural and nutraceutical adjuvants reflects a growing movement toward integrative oncology—an approach that complements pharmacologic treatments with dietary and botanical interventions supported by emerging evidence. These agents often exert multifaceted effects, including antioxidant, anti-inflammatory, immunomodulatory, and cytoprotective actions, which help the body better tolerate chemotherapy. While pharmacologic adjuvants remain the mainstay of supportive care, nutraceuticals may provide synergistic benefits that enhance recovery, resilience, and overall well-being ^[11,12] However, consistent clinical translation depends on standardized formulations, improved bioavailability, and rigorous validation through controlled studies. The following subsections outline prominent nutraceutical candidates and summarize key findings regarding their mechanisms and therapeutic potential.

Table 3: Natural / Nutraceutical Adjuvants for Chemotherapy-Induced Toxicities

5. Non-Pharmacological Adjuvant Therapies

In recent years, non-pharmacological adjuvant therapies have become integral components of comprehensive cancer care. Rather than addressing toxicity through drugs alone, these interventions emphasize physical, psychological, and behavioral well-being, providing multidimensional support throughout chemotherapy. They reduce symptom burden, enhance resilience, and improve overall quality of life. Increasing inclusion of these modalities in global oncology guidelines highlights a paradigm shift toward holistic and patient-centered supportive care. ^[13]

Table 4: Non-Pharmacological Adjuvant Therapies for side effects

6. Formulation Strategies and APIs

Recent advances in formulation science have reshaped how chemotherapy and adjuvant agents are designed and delivered, fundamentally improving their safety and efficacy profiles. The primary objective is to refine drug delivery by enhancing tumor selectivity, reducing systemic exposure, and increasing patient tolerability. These innovations—spanning nanotechnology, biopharmaceutics, and targeted delivery—reflect a broader shift toward precision-based supportive oncology.

6.1 Liposomal and PEGylated Formulations

Liposomal and PEGylated systems have transformed chemotherapeutic delivery by optimizing pharmacokinetics and biodistribution. Encapsulation of cytotoxic agents within lipid vesicles or polymeric coatings reduces plasma peaks and minimizes exposure to healthy tissue.[14] Pegylated liposomal doxorubicin (PLD) is a notable example that significantly lessens anthracycline-related cardiotoxicity while maintaining antitumor potency. The polyethylene glycol (PEG) layer extends circulation time and promotes preferential tumor accumulation via the enhanced permeability and retention (EPR) effect. Similar liposomal versions of cisplatin and paclitaxel also demonstrate reduced nephrotoxicity and neurotoxicity compared to their conventional forms.^[15]

6.2 Nanocarriers and Targeted Drug Delivery

Nanocarriers—including polymeric nanoparticles, micelles, dendrimers, and solid lipid nanoparticles—enable controlled drug release and improved solubility.^[16] Their tunable size, charge, and surface ligands allow precise tumor targeting while sparing healthy tissues. For instance, PLGA-based nanoparticles co-encapsulating chemotherapeutic and protective agents have shown reduced oxidative stress and lower organ toxicity. Stimuli-responsive nanocarriers—triggered by pH, temperature, or redox gradients—further enhance site-specific release and reduce collateral damage. ^[17]

6.3 Self-Emulsifying and Nanoemulsion Systems

Poorly water-soluble active pharmaceutical ingredients (APIs), such as curcumin or resveratrol, often suffer from erratic absorption. Self-nanoemulsifying (SNEDDS) and self-microemulsifying (SMEDDS) systems address this by spontaneously forming fine emulsions upon contact with gastrointestinal fluids, greatly improving dissolution and absorption. ^[18] These systems can also co-encapsulate synergistic agents, amplifying therapeutic efficacy while minimizing toxicity. ^[19]

6.4 Mucoadhesive and Localized Delivery Systems

Mucoadhesive drug delivery platforms are particularly promising for localized prevention of mucositis and gastrointestinal injury. By adhering to mucosal tissues, polymer-based films or gels sustain drug release at the target site. Chitosan- and carbopol-based systems delivering agents like honey, glutamine, or curcumin have shown significant improvement in mucosal protection and comfort. ^[20] These systems exemplify how targeted local delivery minimizes systemic exposure while enhancing therapeutic effect. ^[21]

6.5 Prodrug and Controlled-Release Strategies

Prodrug technologies modify active compounds into inactive precursors that become therapeutically active after enzymatic conversion in vivo, improving selectivity and minimizing systemic toxicity. Controlled-release systems—such as hydrogels, microspheres, or biodegradable implants—maintain steady drug levels, preventing the concentration spikes that often precipitate adverse reactions. ^[22] These approaches are particularly effective for agents with narrow therapeutic windows or dose-dependent toxicities.

6.6 Biosimilars and Biobetters

Biosimilars—highly similar versions of biologic drugs—have significantly increased global access to key supportive therapies such as G-CSFs and erythropoiesis-stimulating agents (ESAs). Comparative studies demonstrate equivalent efficacy, safety, and immunogenicity to original biologics ^[23,24]. Biobetters, or next-generation biologics, incorporate molecular improvements that extend half-life, reduce immunogenic potential, or enhance receptor affinity, representing a new frontier in adjuvant pharmacotherapy. ^[25] Harmonized guidelines from the FDA, EMA, and WHO ensure consistent evaluation of these complex biologics. ^[26]

6.7 Nanopharmaceuticals and Regulatory Integration

Nanopharmaceuticals—including liposomal, polymeric, and metallic nanoparticle formulations—occupy a rapidly evolving regulatory landscape. Agencies such as the FDA, EMA, and WHO now mandate detailed physicochemical characterization covering particle size, charge, release kinetics, and stability. ^[27] Recent guidance from the EMA (2024) and MHRA (2025) emphasizes the use of standardized analytical and comparability frameworks for nano-enabled formulations. ^[28] The integration of Quality by Design (QbD) and risk-based assessment models ensures reproducible manufacturing and safety compliance. ^{[29, 30]}

6.8 Synergistic Formulation Approaches

Recent innovations increasingly focus on dual-delivery systems that combine cytotoxic and protective agents within a single nanocarrier. For example, co-encapsulation of doxorubicin with curcumin or cisplatin with resveratrol within nanoparticles has been shown to decrease cardiotoxicity and nephrotoxicity without compromising antitumor efficacy. ^[31,32] These intelligent platforms exemplify how drug delivery can evolve from passive transport to dynamic, toxicity-mitigating systems.

6.9 Clinical and Translational Implications

Advances in formulation technology are redefining adjuvant therapy by transitioning from reactive symptom management to proactive toxicity prevention. The success of these technologies, however, relies on interdisciplinary collaboration among oncologists, formulation scientists, and regulatory authorities. Key challenges remain—scaling production, ensuring affordability, and maintaining long-term safety oversight. ^[33,34] As these innovations mature, they promise to bridge the gap between laboratory research and real-world oncology practice, laying the foundation for precision-driven supportive care.

7. Regulatory & Safety Considerations

The translation of adjuvant therapies from laboratory innovation to clinical practice depends on robust regulatory oversight and continuous safety evaluation. Agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) provide structured frameworks to ensure product quality, efficacy, and patient protection throughout the entire product lifecycle. As oncology embraces increasingly complex modalities—such as nanomedicines, liposomal systems, biosimilars, and nutraceutical-pharmaceutical hybrids—regulatory science must evolve to balance innovation with safety. ^[35]

Table 5: International Regulatory Guidelines Relevant to Adjuvants and Advanced Formulation